Table 3.
The estimated annual case load of serious fungal infections in Ethiopia.
| Fungal Infection | Predominant Groups at Risk | Rate Per 100,000 | Estimated Number of Cases |
|---|---|---|---|
| Cryptococcosis | AIDS | 9.4 | 9900 |
| PCP | AIDS | 12.1 | 12,700 |
| IA | Haematological Malignancy, lung cancer, 4% of AIDS deaths and 1.3% of COPD admissions to hospital |
10.9 | 11,500 |
| CPA | Tuberculosis patients and other respiratory disorders | 14.5 | 15,200 |
| ABPA | Adult asthma patients | 28.6 | 30,100 * |
| SAFS | Adult asthma patients | 38.9 | 40,900 * |
| Candidaemia | Hospitalised patients |
5.0 | 5300 |
| Candida peritonitis | Post-surgical patients |
0.8 | 800 |
| Oral candidiasis | HIV patients | 72.7 | 76,300 |
| Oesophageal candidiasis | HIV infection | 53.2 | 55,900 |
| Recurrent vaginal candidiasis |
Adult women | 1399 | 1,469,100 |
| Tinea capitis | 4–14-year-old children with poor hygiene | 6716.0 | 7,051,700 |
| Total burden estimated | 8,738,300 |
ABPA, allergic bronchopulmonary aspergillosis; IA, invasive aspergillosis; SAFS, severe asthma with fungal sensitisation; CPA, chronic pulmonary aspergillosis; COPD, chronic obstructive pulmonary disease. * Duplication between ABPA and SAFS is likely as both are sensitised to Aspergillus.